Related Experiment Videos
The incidence of thromboembolic disease
Insights
This study identified thromboembolic risks in orthopedic surgery patients. It recommends prophylactic anticoagulation therapy based on patient risk classification to prevent blood clots.
Area of Science:
- Orthopedic Surgery
- Thromboembolism Research
- Patient Risk Stratification
Background:
- Thromboembolism poses a significant risk in orthopedic surgery patients.
- Accurate risk assessment is crucial for informed consent and preventative strategies.
- Current guidelines require refinement for specific orthopedic patient populations.
Purpose of the Study:
- To determine the incidence of thromboembolism in a large cohort of orthopedic patients.
- To stratify patients into risk classes based on orthopedic diagnosis and history.
- To guide prophylactic anticoagulation therapy decisions.
Main Methods:
- A survey of 7986 orthopedic patients undergoing 5966 operations over three years.
- Analysis of thromboembolic risks correlated with specific orthopedic diagnoses.
- Classification of patients into low-risk (Class 1), medium-risk (Class 2), and high-risk (Class 3) groups.
Main Results:
- Class 1 (low-risk) patients require no anticoagulation.
- Class 2 (medium-risk) patients benefit from dextran or aspirin.
- Class 3 (high-risk) patients necessitate warfarin therapy.
- Mortality rates: 0.26% (Class 2, excluding hip), 2.9% (spinal cord injury), 2.2% (hip surgery).
Conclusions:
- A risk-stratified approach to prophylactic anticoagulation is effective in orthopedic surgery.
- Tailored therapy based on patient classification can mitigate thromboembolic events.
- This framework aids in informed consent and optimizes patient management.
Abstract:
The incidence of thromboembolism was determined by a survey of 7986 orthopedic patients who had 5966 operations at a university hospital during a three-year period. Patients were analyzed to determine thromboembolic risks with respect to the orthopedic diagnosis to assist in providing the patient with informed consent and to identify patients who need prophylactic anticoagulation therapy. The patient population was divided into three risk classes: Class 1, low-risk patients, including children, all upper-extremity patients, and adult non-surgical ambulatory rehabilitation patients; Class 2, medium-risk patients, including all adult lower-extremity patients and patients with spine problems and no history of thromboembolic disease; Class 3, high-risk patients, including all patients with a previous history of thromboembolic disease or venous stasis disease. Class 1 patients require no prophylactic anticoagulation, Class 2 patients should be treated with dextran or aspirin, and Class 3 patients should be treated with warfarin. The calculated mortality for Class 2 patients, excluding hip problems, is 0.26%; mortality for acute spinal cord injuries is 2.9% and for hip surgery 2.2%.